Sanofi Genzyme, a biotech company and the speciality care business of global healthcare specialist Sanofi, has brought in Consilium as its corporate comms adviser.
Sanofi Genzyme develops and distributes therapeutic solutions focusing on patients’ needs. Diabetes medicines and vaccines are among its products.
Consilium will support the Paris-listed Sanofi Genzyme in the UK and Ireland. Consilium Partners Chris Gardner and Amber Fennell lead the brief with support from Chris Welsh and Lindsey Neville.
The team will work with Sanofi Genzyme’s Henry Featherstone, director of public affairs, and Stefanie Holman, corporate communications manager.
Gardner said: “As an independent strategic communications agency focused on healthcare, it is very exciting to engage with Sanofi Genzyme as the company establishes itself as the specialty care business unit of Sanofi. We look forward to working with the company as it builds on its existing reputation in rare diseases and MS and continues to dedicate itself to making a positive impact on the lives of people with serious diseases.”